Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36075
Title: | Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis | Authors: | Simpson-Yap, Steve DE BROUWER, Edward Kalincik, Tomas Rijke, Nick Hillert, Jan A. Walton, Clare Edan, Gilles Moreau, Yves Spelman, Tim GEYS, Lotte PARCIAK, Tina Gautrais, Clement Lazovski, Nikola PIRMANI, Ashkan Ardeshirdavanai, Amin Forsberg, Lars Glaser, Anna McBurney, Robert Schmidt, Hollie Bergmann, Arnfin B. Braune, Stefan Stahmann, Alexander Middleton, Rodden Salter, Amber Fox, Robert J. van der Walt, Anneke Butzkueven, Helmut Alroughani, Raed Ozakbas, Serkan Rojas, Juan, I van der Mei, Ingrid Nag, Nupur Ivanov, Rumen do Olival, Guilherme Sciascia Dias, Alice Estavo Magyari, Melinda Brum, Doralina Mendes, Maria Fernanda Alonso, Ricardo N. Nicholas, Richard S. Bauer, Johana Chertcoff, Anibal Sebastian Zabalza, Anna Arrambide, Georgina Fidao, Alexander Comi, Giancarlo PEETERS, Liesbet |
Issue Date: | 2021 | Publisher: | LIPPINCOTT WILLIAMS & WILKINS | Source: | Neurology, 97 (19) , p. E1870 -E1885 | Abstract: | Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1-12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. Results Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01-2.41; aOR 2.43, 95% CI 1.48-4.02) and ICU admission (aOR 2.30, 95% CI 0.98-5.39; aOR 3.93, 95% CI 1.56-9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54-10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29-2.38; aOR 2.76, 95% CI 1.87-4.07) and ICU admission (aOR 2.55, 95% CI 1.49-4.36; aOR 4.32, 95% CI 2.27-8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09-12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13-3.07; aOR 2.88, 95% CI 1.68-4.92) and ICU admission (aOR 2.13, 95% CI 0.85-5.35; aOR 3.23, 95% CI 1.17-8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71-17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. Discussion Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19. | Notes: | Peeters, L (corresponding author), Hasselt Univ, Data Sci Inst, Biomed Res Inst, Hasselt, Belgium. liesbet.peeters@uhasselt.be |
Document URI: | http://hdl.handle.net/1942/36075 | ISSN: | 0028-3878 | e-ISSN: | 1526-632X | DOI: | 10.1212/WNL.0000000000012753 | ISI #: | WOS:000713678100016 | Rights: | This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
e1870.full.pdf | Published version | 748.25 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
129
checked on Oct 14, 2024
Page view(s)
32
checked on Jul 20, 2022
Download(s)
16
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.